TCTMD’s Top 10 Most Popular Stories for May 2017
Meeting news from EuroPCR and SCAI, a catheter recall, and a study questioning sodium guidelines topped the list this month.
Meeting news from SCAI and EuroPCR 2017 dominated headlines this month. Top stories included new information on scaffold thrombosis with the Absorb BVS, updates on instantaneous wave-free ratio (iFR) versus fractional flow reserve (FFR), cataract risks with radiation exposure, the best antiplatelet drug at 30 days after PCI, and sodium guidelines plus results from the EUROCTO and REPRISE III trials, among others. May 2017 was also a busy month for feature stories on TCTMD, which looked at everything from the safety of very aggressive LDL lowering to India’s decision to put a price cap on stents.
Unlike in the ABSORB studies, even adhering to good implantation techniques failed to limit the risk of device thrombosis.
The single-center study has economic and clinical implications for a strategy already in use in some parts of the world.
The data might not be enough to convince staunch CTO PCI opponents, but they should inform guidelines, the lead investigator says.
Lotus carried low rates of death, stroke, and paravalvular leak, but pacemaker implantations were higher than with CoreValve.
Based on eye exams conducted at last year’s SCAI meeting, investigators say 47% of operators screened had radiation-related damage.
Individuals were more likely to have low systolic and diastolic blood pressures if their sodium intake was higher than currently recommended.
Strut size, implantation techniques, and PCSK9 inhibitors: everything was on the table during an innovation session that kicked off EuroPCR.
Combined data from DEFINE-FLAIR and iFR-SWEDEHEART suggest that clinical presentation may influence functional assessment results.
Specific lots of the devices have been recalled due to potential difficulty in removing the protective balloon sheath, an issue that has resulted in at least one patient death.
The single-arm study found low rates of target vessel failure at 1 year, but with no comparator arm, some questions remain.
Experts say FOURIER helped assuage concerns over cognitive effects, cataracts, and diabetes but that many more years of data are needed.
Just how many European centers will still use the bioresorbable scaffold? Turns out the actual number is difficult to pin down.
Coronary stents in India now cost a fraction of their former price—by government decree. But will patients see the benefits?